Key Highlights
- Niki BioSolutions shares were down 8.28% to USD 1.55 in pre-market trading on November 3, 2026.
- No company announcement dated November 2 or November 3, 2026 was identified in the research for this article.
- A Partnership for plasma based APOE genotyping was announced on October 14, 2026.
- Net income was reported at a loss of about USD 2.25 million, with about 2.94 million shares outstanding as of late October 2026.
- The company filed a mixed securities shelf of USD 75 million in early September 2026, according to reported filings.
What is behind the pre-market dip (down USD 0.1399, 8.28%)
Niki BioSolutions (NASDAQ:NIKI) was down 8.28% to USD 1.55 in pre-market trading on November 3, 2026. The implied Monday November 2, 2026 close is about USD 1.69 (calculated).
Searches found no company press release or regulatory filing dated November 2 or November 3, 2026. With a Market Value in the single digit millions of dollars and very small trading volume, a move of this size can come from a handful of orders. That is an inference, not a confirmed cause.
Recent company updates
The company, which was formerly Aptorum Group Limited, said in July 2026 that the post Merger company would trade on Nasdaq as NIKI following its combination with DiamiR Biosciences. Shareholders of the predecessor approved the merger on June 10, 2026.
On October 14, 2026, the company announced a partnership with the Global Alzheimer's Platform Foundation to provide plasma based APOE genotyping for the Bio-Hermes-002 study. On October 16, 2026, its Rett syndrome biomarker program was featured in a research tool series from the International Rett Syndrome Foundation.
Business background
Niki BioSolutions is a biotechnology company that now combines a blood based biomarker diagnostics platform, focused on neurodegenerative conditions such as Alzheimer's disease, with a legacy pipeline in oncology and infectious diseases. Earlier descriptions of the company listed SACT-1, in Phase 1 trials for neuroblastoma, and ALS-4, in Phase 1 trials for bacterial infections.
In September 2026, the company said it had partnered with a genomics firm to strengthen the bioinformatics and statistical work behind its Alzheimer's testing pipeline. Its head office is listed in Princeton, New Jersey.
Balance sheet and risks
Reported Net Income was a loss of about USD 2.25 million, equal to a loss of USD 2.86 per share, with about 2.94 million shares outstanding. The market value was about USD 5.97 million as of October 21, 2026, which is small for a company running clinical and diagnostic programs.
A USD 75 million mixed securities shelf, if used, could dilute existing holders. At under USD 5, the shares are a penny stock, and such shares can carry high volatility, thin Liquidity and Nasdaq listing risk. The 52 week range of USD 0.60 to USD 12.24 shows how wide recent swings have been.
What to watch next
Investors will watch for the company's next quarterly report, any update on the biomarker partnerships, and whether the shelf is used for an offering. Any Nasdaq notice about bid price or stockholders' Equity would also be visible in regulatory filings.






Please wait processing your request...